BiVictriX Therapeutics PLC
LSE:BVX
Intrinsic Value
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. [ Read More ]
The intrinsic value of one
BVX
stock under the Base Case scenario is
338.71
GBX.
Compared to the current market price of 11.5 GBX,
BiVictriX Therapeutics PLC
is
Undervalued by 97%.
BiVictriX Therapeutics PLC's market capitalization is 9.5m GBX.
BVX stock price is 11.5 GBX.
BVX stock price (11.5 GBX) is 97% less than its Intrinsic Value (338.71 GBX).
BVX. Open Relative Valuation
BVX has upside potential of 485% compared to the average analyst price target.
Open Wall St Estimates
BVX has negative Free Cash Flow for the last twelve months.
BVX has negative Operating Income for the last twelve months.
BVX has negative Net Income for the last twelve months.
BVX's ROE (Return on Equity) for the past 12 months is negative and is equal to -59%.
BVX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -223%.
BVX's D/E (Debt to Equity) is very low and is equal to 0.08.
BVX has negative three-year average ROE (Return on Equity): -80%. The company is not efficient at transforming stockholders' equity into net income.
BVX has negative three-year average ROIC (Return on Invested Capital): -489%. The company is not efficient at using invested capital to generate operating income.
BVX's short-term assets (3m GBP) exceed its short-term liabilties (409k GBP).
BVX's long-term assets (3m GBP) exceed its long-term liabilties (625k GBP).
BVX has negative Net Debt. This means that the company has more cash and short-term investments (2m GBP) than debt (216k GBP).
BVX's Altman Z-Score is very high and is equal to 5.36.
Fundamental Analysis
BiVictriX Therapeutics PLC
Balance Sheet Decomposition
BiVictriX Therapeutics PLC
| Current Assets | 2.8m |
| Cash & Short-Term Investments | 1.9m |
| Receivables | 898k |
| Non-Current Assets | 655k |
| PP&E | 655k |
| Current Liabilities | 409k |
| Accounts Payable | 214k |
| Other Current Liabilities | 195k |
| Non-Current Liabilities | 216k |
| Long-Term Debt | 216k |
Earnings Waterfall
BiVictriX Therapeutics PLC
|
Revenue
|
0
GBP
|
|
Operating Expenses
|
-2.8m
GBP
|
|
Operating Income
|
-2.8m
GBP
|
|
Other Expenses
|
487k
GBP
|
|
Net Income
|
-2.3m
GBP
|
Free Cash Flow Analysis
BiVictriX Therapeutics PLC
BVX Profitability Score
Profitability Due Diligence
BiVictriX Therapeutics PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
BiVictriX Therapeutics PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
BVX Solvency Score
Solvency Due Diligence
BiVictriX Therapeutics PLC's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
BiVictriX Therapeutics PLC's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BVX Price Targets Summary
BiVictriX Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
BVX
is 67.32 GBX
with a low forecast of 66.66 GBX and a high forecast of 69.3 GBX.
Shareholder Return
BVX Price
BiVictriX Therapeutics PLC
| Average Annual Return | -13.34% |
| Standard Deviation of Annual Returns | 41.05% |
| Max Drawdown | -69% |
| Market Capitalization | 9.5m GBX |
| Shares Outstanding | 82 526 085 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
BiVictriX Therapeutics PLC
Country
Industry
Market Cap
Dividend Yield
Description
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
You don't have any saved screeners yet
